Exploring the Potential Energy Surface for the Interaction of Sterically Hindered Trichloro(diethylenetriamine)gold(III) Complexes with Water

S-Se oxidative addition to auranofin derivatives: a DFT study

Oxidative addition of the S-Se bond to Au(I) complexes is discussed for a series of 26 auranofin (AF) derivatives. AF and its analogues are Au(I) complexes with recognized anticancer activity that act by binding and inhibiting the thioredoxin reductase (TrxR) enzyme. Generally, the oxidative addition to Au(I) is a sluggish reaction under mild conditions (i.e., a high activation barrier - ΔH‡), which is also verified here for AF, ΔH‡ = 33.0 kcal mol-1. However, we predicted that subtle changes in the AF ligands can make the process feasible under standard conditions. For instance, the exchange of -PEt3 by -P(Et2)(OEt), which is a weaker electron σ-donor, reduced the activation barrier to 17.1 kcal mol-1. Furthermore, substitution of the -SAtg ligand by -Cl- leads to a ΔH‡ value of 22.5 kcal mol-1. Overall, the reaction is driven by the nucleophilic attack of the S-Se bond on the Au(I) center, attributed mainly to the charge transfer (4p)Se → (6p)Au, which characterizes the addition step. At the transition state (TS) point, the (5d)Au → σ*(S-Se) charge transfer becomes relevant, facilitating the S-Se bond breakage and the oxidation step. In addition to the electron transfers, the strain energy to deform the linear Au(I) geometry to the tetracoordinated Au(III) arrangement in the TS structure plays a primary role in explaining the trends in the activation barriers. Finally, the activation barrier (ΔH‡) and reaction energy (ΔH°) were correlated for most of the complexes studied, which suggests that the reaction passes through a late or product-like TS and, therefore, the steric and electronic factors affecting ΔH‡ also act on ΔH°. Overall, the results presented here might open up a new field of investigation for interactions between AF derivatives and TrxR, which contributes to a full understanding of the biological mechanism of action of these species.

The role of tridentate ligands on the redox stability of anticancer gold(III) complexes

Gold(III) complexes are promising compounds for cancer chemotherapy, whose action depends on their redox stability. In this context, the choice of ligands is crucial to adjust their reactivity and biological response. The present study addressed the effect of the gold coordination sphere on the reduction potential (E^o) for ten gold(III) complexes containing five or six-membered rings tridentate ligands - [Au^III(trident)Cl]³⁺ⁿ (trident = N^N^N, C^N^N, C^C^N, C^N^C, and N^C^N). The calculated E^o covered a broad range of 2500 mV with the most stable complexes containing two AuC bonds (E^o = -1.85 V for [Au^III(C^C^N)Cl] - f). For complexes with one AuC bond, the N^C^N ligands stabilize the gold(III) complex more efficiently than N^N^C; however, the inclusion of the non-innocent ligand bipy (2,2'-bipyridine) in N^N portion provides an extra stabilization effect. Among the derivatives with one AuC bond, [Au^III(N^N^C)Cl]⁺ (N^N = bipy) (a) showed E^o = -1.20 V. For the complexes with N^N^N ligands, E^o was positive and almost constant (+0.60 V). Furthermore, the kinetics for ligand exchange reactions (Cl^-/H₂O, H₂O/Cys and Cl^-/Cys) were monitored for the most stable compounds and the energy profiles compared to the reduction pathways.

A Novel Hybrid of Chloroquine and Primaquine Linked by Gold(I): Multitarget and Multiphase Antiplasmodial Agent

Plasmodium parasites kill 435 000 people around the world every year due to unavailable vaccines, a limited arsenal of antimalarial drugs, delayed treatment, and the reduced clinical effectiveness of current practices caused by drug resistance. Therefore, there is an urgent need to discover and develop new antiplasmodial candidates. In this work, we present a novel strategy to develop a multitarget metallic hybrid antimalarial agent with possible dual efficacy in both sexual and asexual erythrocytic stages. A hybrid of antimalarial drugs (chloroquine and primaquine) linked by gold(I) was synthesized and characterized by spectroscopic and analytical techniques. The CQPQ-gold(I) hybrid molecule affects essential parasite targets, it inhibits β-hematin formation and interacts moderately with the DNA minor groove. Its interaction with PfTrxR was also examined in computational modeling studies. The CQPQ-gold(I) hybrid displayed an excellent in vitro antimalarial activity against the blood-stage of Plasmodium falciparum and liver-stage of Plasmodium berghei and efficacy in vivo against P. berghei, thereby demonstrating its multiple-stage antiplasmodial activity. This metallic hybrid is a promising chemotherapeutic agent that could act in the treatment, prevention, and transmission of malaria.

Novel antitumor adamantane-azole gold(I) complexes as potential inhibitors of thioredoxin reductase

Gold complexes that could act as antitumor agents have attracted great attention. Heterocyclic compounds and their metal complexes display a broad spectrum of pharmacological properties. The present study reports the preparation and characterization of four novel gold(I) complexes containing tertiary phosphine and new ligands 5-adamantyl-1,3-thiazolidine-2-thione, 3-methyladamantane-1,3,4-oxadiazole-2-thione. Spectroscopic data suggest that gold is coordinated to the exocyclic sulfur atom in all cases, as confirmed by X-ray crystallographic data obtained for complex (1) and supported by quantum-mechanical calculations. The cytotoxicity of the compounds has been evaluated in comparison to cisplatin and auranofin in three different tumor cell lines, colon cancer (CT26WT), metastatic skin melanoma (B16F10), mammary adenocarcinoma (4T1) and kidney normal cell (BHK-21). The gold complexes were more active than their respective free ligands and able to inhibit the thioredoxin reductase (TrxR) enzyme, even in the presence of albumin. Molecular modeling studies were carried out to understand the interaction between the compounds and the TrxR enzyme, considered as a potential target for new compounds in cancer treatment. The docking results show that the adamantane ring is essential to stabilize the ligand-enzyme complex prior the formation of covalent bond with gold center. The structure of the new gold compounds was established on the basis of spectroscopic data, DFT calculations and X-ray diffraction. TrxR inhibition was evaluated and the results correlated with the assays in tumor cells, suggesting the TrxR as possible target for these compounds.

Aquaporin inhibition by gold(III) compounds: new insights

Aquaporins (AQPs) are membrane water/glycerol channels with essential roles in biological systems, as well as being promising targets for therapy and imaging. Using a stopped-flow method, a series of gold(III), platinum(II) and copper(II) complexes bearing nitrogen donor ligands, such as 1,10-phenatroline, 2,2'-bipyridine, 4,4'-dimethyl-2,2'-bipyridine, 4,4'-diamino-2,2'-bipyridine and 2,2';6',2"-terpyridine, were evaluated in human red blood cells expressing AQP1 and AQP3, responsible for water and glycerol movement, respectively. The results showed that the gold(III) complexes selectively modulate AQP3 over AQP1. Molecular modeling and density functional theory (DFT) calculations were subsequently performed to rationalize the observations and to investigate the possible molecular mechanism through which these gold compounds act on their putative target (AQP3). In the absence of any crystallographic data, a previously reported homology model was used for this purpose. Combined, the findings of this study show that potent and selective modulation of these solute channels is possible, however further investigation is required into the selectivity of this class of agents against all AQP isoforms and their potential therapeutic uses.